Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2,012	2,730	3,106	2,886	2,194	1,618
Short-Term Investments	7,785	8,115	4,636	2,809	1,393	1,597
Cash & Short-Term Investments	9,797	10,845	7,742	5,695	3,587	3,214
Cash Growth	-1.18%	40.07%	35.96%	58.76%	11.60%	14.39%
Accounts Receivable	5,790	5,317	5,023	5,059	3,112	2,693
Other Receivables	317.4	350	305.6	977.5	1,003	92.2
Receivables	6,107	5,667	5,329	6,037	4,115	2,786
Inventory	3,018	2,581	2,402	1,951	1,917	1,416
Prepaid Expenses	412	386.6	411.2	332.4	160.8	273.7
Total Current Assets	19,334	19,479	15,884	14,015	9,779	7,689
Property, Plant & Equipment	4,439	4,224	3,834	3,482	3,222	2,890
Long-Term Investments	8,651	5,471	6,640	6,878	3,195	3,312
Other Intangible Assets	1,120	1,039	915.5	6.7	-	-
Long-Term Deferred Tax Assets	3,015	2,575	1,724	876.9	858.9	824.2
Other Long-Term Assets	883.2	291.8	216.9	176.1	108.9	89.1
Total Assets	37,442	33,080	29,215	25,435	17,163	14,805
Accounts Payable	497.3	606.6	589.2	564	475.5	418.1
Accrued Expenses	2,537	2,316	2,054	1,593	1,609	1,162
Current Portion of Leases	-	19	12.4	719.7	-	-
Current Income Taxes Payable	-	-	-	326.3	19.5	49.4
Current Unearned Revenue	627.2	481.5	485.3	442	577.7	382.1
Other Current Liabilities	-	-	-	287.4	16.1	85
Total Current Liabilities	3,661	3,423	3,141	3,933	2,697	2,097
Long-Term Debt	1,984	1,983	1,981	1,980	1,979	-
Long-Term Leases	720	788.7	775.8	-	717.2	713.9
Long-Term Unearned Revenue	207.4	126.7	69.8	73.3	57.8	105.3
Other Long-Term Liabilities	1,544	785.4	582.2	680.2	687.1	799.7
Total Liabilities	8,116	7,107	6,551	6,666	6,138	3,716
Common Stock	0.1	0.1	0.1	0.1	0.1	0.1
Additional Paid-In Capital	12,703	11,354	9,949	8,088	6,716	4,429
Retained Earnings	30,755	27,260	23,307	18,968	10,893	7,380
Treasury Stock	-14,192	-12,560	-10,353	-8,261	-6,613	-739.9
Comprehensive Income & Other	60.2	-80.9	-238.8	-26.2	29.3	21.1
Shareholders' Equity	29,326	25,973	22,664	18,769	11,025	11,090
Total Liabilities & Equity	37,442	33,080	29,215	25,435	17,163	14,805
Total Debt	2,704	2,791	2,770	2,700	2,696	713.9
Net Cash (Debt)	15,583	13,451	11,565	9,833	4,027	5,757
Net Cash Growth	19.97%	16.31%	17.61%	144.18%	-30.05%	49.29%
Net Cash Per Share	135.36	118.30	101.89	87.64	34.99	50.24
Filing Date Shares Outstanding	107.59	107.46	106.73	106.44	104.14	108.86
Total Common Shares Outstanding	107.8	107.12	107	106.57	103.96	109.12
Working Capital	15,673	16,056	12,743	10,082	7,082	5,593
Book Value Per Share	272.04	242.47	211.81	176.11	106.05	101.63
Tangible Book Value	28,206	24,935	21,749	18,762	11,025	11,090
Tangible Book Value Per Share	261.65	232.78	203.26	176.05	106.05	101.63
Land	-	283.1	264.5	248	241.2	230.8
Buildings	-	2,423	2,270	2,089	1,891	1,683
Machinery	-	1,940	1,803	1,662	1,395	1,156
Construction In Progress	-	1,345	980.5	767.7	724.5	644.8
Leasehold Improvements	-	133.9	114.3	113.9	100.5	97.6

Source: S&P Capital IQ. Standard template. Financial Sources.